Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16726537 | 0.85 | CA2 (0.55) | CA2CA12CA1CA7CA9 | |
| SCHEMBL8337382 | 0.85 | CA12 (0.59) | CA2CA12CA1CA7CA9 | |
| SCHEMBL9211531 | 0.83 | CA2 (0.57) | CA2CA12CA1CA7CA9 | |
| SCHEMBL5211170 | 0.83 | CA2 (0.57) | CA2CA12CA1CA7CA9 | |
| SCHEMBL4689684 | 0.83 | HTR2A (0.51) | HTR2ASLC6A4MAPTALDH1A1HTT | |
| SCHEMBL13978302 | 0.82 | CA2 (0.61) | CA2CA12CA1CA7CA9 | |
| SCHEMBL10849608 | 0.82 | L3MBTL4 (0.58) | CA2CA12CA1CA7CA9 | |
| SCHEMBL4392307 | 0.81 | CA2 (0.55) | CA2CA12CA1CA7CA9 | |
| SCHEMBL4689682 | 0.81 | PARP15 (0.60) | APPALDH1A1LMNAHPGDHTT | |
| SCHEMBL15450963 | 0.81 | CA2 (0.59) | CA2CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858885-B2 | Cellulosic complex and applications thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-02 | — | — | US | disclosed |
| US-11858885-B2 | Cellulosic complex and applications thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-02 | — | — | US | disclosed |
| US-20220153669-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-05-19 | — | — | US | disclosed |
| US-20220153669-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-05-19 | — | — | US | disclosed |
| WO-2020202179-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020202179-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153669-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | CEL, DBF4, NAF1 | CA2 329/4885CA12 187/4885CA1 675/4885 |
| US-11858885-B2 | Cellulosic complex and applications thereof | CEL, DBF4, NAF1 | CA2 329/4885CA12 187/4885CA1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.